MYUNGMOON Pharm co.,Ltd

A017180

KR7017180001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 22/05/2024 BST			5-day change	1st Jan Change
2,050 ^KRW	+1.23%		-1.68%	-10.28%

03-20	MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	CI

Myungmoon Pharm. Co., LTD.(KOSE:A017180) dropped from S&P Global BMI Index

September 23, 2019 at 05:00 am

Latest news about MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	11-27	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	11-27	CI
MYUNGMOON Pharm co.,Ltd's Equity Buyback announced on May 25, 2023, has expired with 278,592 shares, representing 0.82% for KRW 674.93 million.	11-24	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023.	28/08/23	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
MYUNGMOON Pharm co.,Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.	25/05/23	CI
MYUNGMOON Pharm co.,Ltd authorizes a Buyback Plan.	24/05/23	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
MYUNGMOON Pharm co.,Ltd(KOSE:A017180) dropped from S&P Global BMI Index	19/09/22	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	15/03/22	CI
MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
M2N Co.,Ltd cancelled the acquisition of an unknow stake in MYUNGMOON Pharm co.,Ltd.	11/11/21	CI
M2N Co.,Ltd agreed to acquire an unknow stake in MYUNGMOON Pharm co.,Ltd.	03/11/21	CI
Woo Seok-min agreed to acquire 2.4% stake in Myungmoon Investment Development Co. Ltd. from MYUNGMOON Pharm co.,Ltd for KRW 2.1 billion.	24/06/21	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) added to S&P Global BMI Index	21/09/20	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) dropped from S&P Global BMI Index	23/09/19	CI
Myungmoon Pharm. Co., LTD. announced that it has received KRW 15 billion in funding from a group of investors	28/01/19	CI
Myungmoon Pharm. Co., LTD. announced that it expects to receive KRW 15 billion in funding from a group of investors	24/01/19	CI
Myungmoon Pharm. Co., LTD.(KOSE:A017180) added to S&P Global BMI Index	24/09/18	CI
Jong-min Kim acquired 0.93% stake in Myungmoon Pharm. Co., LTD. from Woo, Seok-Min for approximately KRW 300 million.	09/01/14	CI

MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MYUNGMOON PHARM CO.,LTD	-10.28%	49.71M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B